randOmized stUdy Using acceleromeTry to Compare Sacubitril/valsarTan and Enalapril in Patients With Heart Failure

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 621 participants.

Also called NCT02900378

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; triple masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 621 participants (enrolled count) (from the registry)
Sponsor
  • Novartis Registry lists this organization as the lead sponsor
Registry
  • NCT NCT02900378
  • EudraCT 2016-003085-32
Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Results first posted
(from the registry)
Countries
Belgium, Bulgaria, Czechia, Denmark, Estonia, Finland, France, Germany, Greece, Iceland, Ireland, Latvia, Lithuania, Netherlands, Norway, Poland, Spain, Sweden, United Kingdom (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT02900378. Randomized; triple masking; primary purpose treatment. Start 2016-12-20 (actual); primary completion 2018-04-11 (actual). Results posted on 2019-09-16.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
randOmized stUdy Using acceleromeTry to Compare Sacubitril/valsarTan and Enalapril in Patients With Heart Failure
Acronym
OUTSTEP-HF
Intervention (Drug)
LCZ696 (Sacubitril/Valsartan)
Intervention (Drug)
Placebo of LCZ696 (Sacubitril/Valsartan)
Intervention (Drug)
Enalapril
Intervention (Drug)
Placebo of Enalapril
Lead sponsor
Novartis Pharmaceuticals (class: industry)

Record details

Record id
cardio:ct-nct02900378
Content hash
7a5a7fca700541abdaca7fb5002f0cdc0011f16e81938565a01e567a8feaa455